Spain· ES:1201428001
GIVLAARI 189 MG/ML SOLUCION INYECTABLE
A givosiran product containing givosiran, registered in Spain by Alnylam Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
Where it is registered
Givosiran is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AX16 (givosiran), each read from that country’s own register.
- This record: Spain, from AEMPS CIMA (Spain)
- 9 of them publish a price we can compare per daily dose
Givosiran · ATC A16AX16
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- givosiran
- Manufacturer
- Alnylam Netherlands B.V.
- Country
- Spain (ES)
- ATC code
- A16AX16
- ATC class
- Givosiran
- Defined daily dose
- 5.8 mg, P
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
105 interactions on record for givosiran.
Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Givosiran · interactions on record
105 records
- 24 severe
- 81 moderate
Most severe, free to view
- EliglustatA16AX10severe
- TemsirolimusL01EG01severe
- EverolimusL01EG02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Givosiran in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandGivlaari
- IcelandGivlaariAlnylam Netherlands B.V.
- PolandGivlaariAlnylam Netherlands B.V.
- SwedenGivlaari 189 mg/ml Injektionsvätska, lösningAlnylam Netherlands B.V.
- CanadaGIVLAARIALNYLAM NETHERLANDS B.V.
- FranceGIVLAARI 189 mg/mL, solution injectableALNYLAM NETHERLANDS (PAYS-BAS)
- United KingdomGivlaari 189mg/1ml solution for injection vialsAlnylam UK Ltd
- NetherlandsGivlaari 189 mg/ml oplossing voor injectieAlnylam Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Givlaari
- Liechtenstein · Givlaari
- Norway · Givlaari
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ced587d8-9a4f-4115-82cf-307c206ed897 GET /v1/drugs/ced587d8-9a4f-4115-82cf-307c206ed897?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":1588053323000}",
"nregistro": "1201428001",
"substance": "givosiran"
}See everything about givosiran.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.